Podcasts about pooled

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Matthew Brown, the Chief Scientific Officer at Genomics England, as they discuss his recent paper ‘Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: Pooled results from Phase 2b/3 trials'.

In this week's issue of Travers Smith's Alternative Insights, we are looking at the long term implications of the development of fund tokenisation. Links:https://www.fca.org.uk/publication/consultation/cp25-28.pdfhttps://www.traverssmith.com/knowledge/knowledge-container/fca-measures-to-support-direct-2-fund-dealing-and-fund-tokenisationhttps://www.theia.org/sites/default/files/2023-11/UK%20Fund%20Tokenisation%20-%20A%20Blueprint%20for%20Implementation.pdf

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Vutrisiran in Transthyretin Amyloidosis: A Pooled Safety Analysis of HELIOS-A and HELIOS-B.

Mehdi H. Shishehbor, DO, MPH, PhD, FACC and F. Aaysha Cader, MBBS, MD, MSc, FACC discuss the analysis of 1-Year Outcomes of Transcatheter Arterialization of Deep Veins: PROMISE II and Pooled PROMISE Studies.

Mehdi H. Shishehbor, DO, MPH, PhD, FACC and F. Aaysha Cader, MBBS, MD, MSc, FACC discuss the analysis of 1-Year Outcomes of Transcatheter Arterialization of Deep Veins: PROMISE II and Pooled PROMISE Studies.

In this JCO Article Insights episode, host Peter Li summarizes "Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST" by Pérol et al, published April 03, 2025, followed by an interview with first author, Dr Maurice Pérol. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Peter Li: Welcome to this episode of JCO Article Insights. I am Dr. Peter Li, JCO's editorial fellow, and today I am joined by Dr. Maurice Pérol on “Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST,” by Pérol et al. At the time of this recording, our guest has disclosures that will be linked in the transcript. Before we start our interview, I want to give our listeners a quick summary of the TRUST study. For those tuning in, the TRUST study is a phase II, single-arm, open-label, nonrandomized, multicenter trial looking at the efficacy and safety of a novel, next-generation ROS1 TKI, taletrectinib, in advanced ROS1-mutated non–small cell lung cancer. While a relatively rare mutation, the prevalence of ROS1 mutations ranges from 0.9% to 2.6% of patients, with a third of patients presenting with brain mets at diagnosis.Current FDA-approved therapies include crizotinib, entrectinib, and repotrectinib, which have varying degrees of efficacy, in-coming with trade-offs in CNS penetrance and safety with newer generations, particularly in the realm of neurological side effects, highlighting an unmet need in this arena. A total of 273 patients with advanced non–small cell lung cancer with confirmed ROS1 mutation were recruited for this study. 160 patients were TKI-naive, while 113 were TKI-experienced with either crizotinib or entrectinib. Patients with asymptomatic brain mets were also allowed to enroll. In the TKI-naive arm, the median age was 57, with 91% of patients having stage IV disease, 20% having no more than one cycle of chemo, and 23% having brain mets at baseline. In the TKI-experienced arm, the median age was 53, with 97% having stage IV disease, 37% having received prior chemo, and about 50% having brain mets. Furthermore, about 10% of the study population had received entrectinib, while more than 90% had received crizotinib. About 10% had a known G2032R acquired resistance mutation. Taletrectinib was dosed at 600 mg daily until disease progression or unacceptable toxicities. The primary endpoint was overall response rate, with secondary endpoints being disease control rate, duration of response, time to response, and progression-free survival. For those with brain mets, intracranial overall response rate and disease control rate were also assessed. Median follow-up time was about 21 months in both cohorts. In the TKI-naive cohort, the overall response rate was 89%, with 8 patients achieving a complete response. Disease control rate was 95%, with a median duration of response of 44.2 months. Time to treatment response was about 1.5 months. Median progression-free survival was 45.6 months, with 52.6% not having progressed at 3 years. While overall survival data were immature, 66% of patients were still alive at 3 years. In the pretreated cohort, overall response rate was 56%, with 5 patients achieving a complete response. Overall response rate was 53% for those who were crizotinib-pretreated and 80% for the entrectinib-pretreated patients. Disease control rate was 88%, and median duration of response was about 16.5 months. Time to treatment response was also 1.5 months, and median progression-free survival was 9.7 months. Median overall survival was not reached, but 77.5% of patients were still alive at 1 year. Responses were consistently seen across subgroup analyses. 17 TKI-naive and 32 TKI-pretreated patients had measurable brain mets. In the TKI-naive arm, intracranial overall response rate was 77%. Disease control rate was 88%, and duration of response was 15 months. In the TKI-pretreated arm, intracranial overall response was 66%, with one patient achieving complete response. The disease control rate was 94%, and duration of response was about a year. For the 13 patients who had a known G2032R mutation, a 62% response rate was noted. Most common treatment-related side effects were AST/ALT elevation, nausea, and vomiting, with most being grade 1 or 2. Most common neurological side effects were dizziness, dysgeusia, and headache. Again, most were grade 1. QTc prolongation is another important adverse event to note, occurring in about 18% of all patients. Discontinuation rate from treatment was only 7%. There were three treatment-related deaths in this study: one from hepatic failure, one from pneumonia in the naive arm, and one from liver dysfunction in the pretreated arm. Dr. Peter Li: Maurice, thank you so much for joining us today to talk about your paper. Would you mind just giving yourself a brief introduction to the listeners out there of who you are? Dr. Maurice Pérol: So, my name is Maurice Perol. I'm a thoracic oncologist working in the Cancer Center of Lyon in France. And I'm involved in clinical research in thoracic oncology. I've been involved for many years now. Dr. Peter Li: Okay. And for listeners out there, don't forget, he's also the primary author of the paper that we just talked about. So, Maurice, let's begin. Can you tell our listeners what is the significance of your study? Dr. Maurice Pérol: Well, the results of these two large phase II studies - TRUST-I, which has been conducted in China, and TRUST-II, which was a global, worldwide phase II study - so, the results place taletrectinib as the TKI with the most favorable efficacy-tolerability ratio of the available ROS1-targeting TKIs, especially in frontline therapy. And this is based on the response rate, which was very impressive, the CNS penetration with a great CNS activity, the duration of response with a compelling 45 months median PFS in frontline setting. The level of activity in pretreated patients after crizotinib or entrectinib was also impressive and similar to that of repotrectinib, for example, but with a more favorable neurological tolerance profile. The toxicity is mainly represented with grade 1 or 2 transaminase elevation, but without clinical symptoms, and GI toxicity, but mainly grade 1 and 2. The neurological toxicity is low, especially for dizziness, showing that taletrectinib spares TrKB in a large part. And finally, there is also a decrease in toxicity over time, especially for GI toxicity and liver toxicities, which allows a very long and a prolonged administration, which is very important in this setting. Dr. Peter Li: These are all excellent points. Can you tell the listeners if there are any limitations that we should be concerned about, about this study? Dr. Maurice Pérol: Sure. This data comes from single-arm phase II studies. So, this is not comparative data. And a phase III trial, which compares taletrectinib to crizotinib, is ongoing to evaluate the superiority of taletrectinib over the standard of care. Another limitation comes from the lack of systematic brain imaging at each tumor evaluation in patients without brain metastases at baseline, not allowing to assess the intracranial PFS in all patients, and which did not allow us to assess the CNS protective issue from taletrectinib, especially in patients without brain metastases at baseline. Dr. Peter Li: Another question that I have is, with this novel TKI now available, how would you recommend the sequencing of these drugs? Would you start with someone on an alternate TKI and then reserve taletrectinib second line or later? Or would you use it upfront? Or does it depend? Dr. Maurice Pérol: Well, it is a very important question, as we have now different available TKIs. Looking at the efficacy-toxicity balance, I would strongly favor the use of taletrectinib in frontline setting, in first line. The response rate, the CNS activity, the duration of response with a very compelling 45 months median PFS, and moreover, the good tolerance profile over time are strong arguments in favor of giving taletrectinib in frontline. Generally speaking, the use of the most active agent as frontline treatment in lung cancer depending on an oncogenic addiction is probably the best way to improve the patient's outcome. This is true for patients with EGFR mutation, for patients with ALK fusions, and this is probably also true for patients with ROS1 fusion. So, I would probably argue in favor of a frontline use of taletrectinib. Dr. Peter Li: Listeners are going to ask, well, if you use taletrectinib upfront, then what are you going to use second line once they progress? Dr. Maurice Pérol: Well, we have some new compounds which are under development today. For example, the NVL-520, which is a very interesting compound, which seems also to be active in case of resistance mutation. But I do think that we have to use the best-in-class TKI in frontline because, you know, the extension of PFS after acquired resistance you can obtain with a second-line TKI is always shorter than the benefit you can obtain by using the most active agent in frontline. And this is true for the majority of oncogenic addiction in lung cancer. Dr. Peter Li: That makes sense. I also noticed that cognitive impairment wasn't listed in the safety table. Is that not an issue that you've observed at all with taletrectinib, or is it still an issue but less so because, like you mentioned earlier, because of its higher selectivity? Dr. Maurice Pérol: Well, this is a good question because we have some ROS1-targeting TKIs like repotrectinib, entrectinib, and even lorlatinib, with some neurological adverse events and some cognitive issues. Taletrectinib is a very selective ROS1-targeting TKI, and it spares very well the TrKB, for example, explaining that we did not observe any cognitive impairment with taletrectinib in the TRUST study, showing also with the low level of other neurological adverse events, dizziness, dysgeusia, for example, the high selectivity of the compound and the preservation of TrKB. So, this is very important when you consider the long duration of treatment in those patients with ROS1 fusion. If you have to take a drug for more than 2, 3, or 4 years, of course, the neurological adverse events are very important, and they can clearly impair the quality of life. So, this is a very important point, the very low level of neurological toxicity of taletrectinib. Dr. Peter Li: And I think that goes to say why you would favor using it frontline as well compared to entrectinib or repotrectinib. Last question that we have for you is: well, what's next? You mentioned there's a phase III trial comparing it to crizotinib. I think one of the questions that a lot of us would have is: why not compare it to one of the newer agents as a comparator arm? Dr. Maurice Pérol: Well, this is a good question. Crizotinib remains the standard of care in many countries for ROS1-positive advanced non–small cell lung cancer outside of the US, especially in Europe, and in particular in patients who do not have brain metastases at diagnosis. Entrectinib has a better CNS penetration, but it did not achieve a better PFS than crizotinib in phase I/II trials, and clearly, it has a less favorable tolerance profile with weight gain, edema, and neurological adverse events. Repotrectinib has overall a level of activity which seems close to that of taletrectinib. So, it makes it difficult to consider a comparative trial that would, for example, test taletrectinib in comparison with repotrectinib because this kind of study would need a very large number of patients and a very late readout. Considering if you have a median PFS of more than 3 or 4 years, it would be very difficult to have results in before 4-5 years. So, from a pragmatic point of view, the comparison of taletrectinib to crizotinib is probably the best way to evaluate in a phase III setting the level of activity of taletrectinib, especially in the CNS, because this study will probably allow us to assess the CNS protective effect of the compound for patients without brain metastates at baseline. So, I think probably it's a pragmatic study that will allow us to confirm the high level of activity and the good tolerance profile of taletrectinib. Dr. Peter Li: Well, thank you, Maurice, so much for speaking about the JCO article, “Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST,” and for all your valuable input today. Thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries, and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on PREVENT Risk Score vs the Pooled Cohort Equations in MESA.

Host: Jacob Sands, MD Guest: Elaine Shum, MD Guest: Estelamari Rodriguez, MD, MPH There was a recent pooled analysis of the TROPION-Lung01 and TROPION-Lung05 studies, which focused on the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients with previously treated EGFR-mutated advanced non-small cell lung cancer (NSCLC). According to the results, Dato-DXd demonstrated an overall response rate of 43 percent, with durable responses and a manageable safety profile. Joining Dr. Jacob Sands to talk more about these findings and their implications are Drs. Elaine Shum and Estelamari Rodriguez. Dr. Shum is an Assistant Professor in the Department of Medicine at NYU Grossman School of Medicine, and Dr. Rodriguez is an Associate Director of Community Outreach, Thoracic Oncology at Sylvester Comprehensive Cancer Center at the University of Miami Health System.

Transcatheter Aortic Valve Replacement With Self-expanding Valves Vs. Balloon-expandable Valves - A Pooled Analysis From Navultra And Neopro2 Registries

When it comes to protecting a loved one with disabilities, few decisions are as overwhelming as choosing the right trustee. But in a world of nonprofit pooled trusts, legal jargon, and alarming headlines about financial misconduct, how do you separate peace of mind from potential pitfalls? In this episode of Parenting Impossible, I break down everything you need to know about Pooled Special Needs Trusts, from how they work to when they make sense. I share hard-earned wisdom as both a lawyer and a special needs parent, guiding you through what questions to ask, how to vet your options, and why sometimes the best Trustee choice isn't family, but a professional with heart and structure. You'll walk away not just more informed, but more empowered. In this episode, you will hear: What a Pooled Trust actually is, and who should consider one. The difference between First-party and Third-party Special Needs Trusts. What went wrong in the recent $100M nonprofit scandal (and how to avoid it). Why transparency, independence, and communication are non-negotiable.   Engage with us: 25% off any courses, masterclasses and minisodes in Special Needs Academy here Join our community: Circle of Care Visit:  https://annettehines.com Read Butterflies and Second Chances LinkedIn: @annette-hines-snc  Instagram: @parentingimpossible Facebook: @SpecialNeedsCompanies Twitter: @SpecialNeedsCo   Follow and Review: We'd love for you to follow us if you haven't yet. Click that purple '+' in the top right corner of your Apple Podcasts app. We'd love it even more if you could drop a review or 5-star rating over on Apple Podcasts. Simply select “Ratings and Reviews” and “Write a Review” then a quick line with your favorite part of the episode. It only takes a second and it helps spread the word about the podcast.  

This special electrophysiology-themed issue of JACC, summarized by Dr. Valentin Fuster, dives into cutting-edge research on atrial fibrillation, pulsed field ablation, sudden cardiac arrest in athletes, and preventive strategies in congenital heart disease. From new therapies like finerenone to breakthrough mapping techniques, this episode captures the evolving sophistication and promise of arrhythmia management in modern cardiology.

NESTE VIDEO FALAREI DA CIENCIA POR TRAS DOS RISCOS DOS CAMPOS ELETROMAGNETICOS GERADOS POR NOSSOS CELULARES, WI FI, 5G, E OUTROS APARELHOS ELETRONICOS. FAREMOS UMA VIAGEM EM TORNO DOS MECANISMOS, ARTIGOS, COMPROVAÇÕES E UMA PITADA DA MINHA OPINIÃO PESSOAL. NO FINAL DO VIDEO DOU 10 PASSOS PARA MELHORAR SEU BEM ESTAR USANDO SEUS EQUIPAMENTOS. COMPARTILHE ESTE VIDEO COM ALGUEM QUE PASSA O DIA NO CELULAR E NÃO LIGA PRA ISSO.REFERENCIAS BIBLIOGRAFICAS:Smith-Roe SL, Wyde ME, Stout MD, Winters JW, Hobbs CA, Shepard KG, Green AS, Kissling GE, Shockley KR, Tice RR, Bucher JR, Witt KL. Evaluation of the genotoxicity of cell phone radiofrequency radiation in male and female rats and mice following subchronic exposure. Environ Mol Mutagen. 2020 Feb;61(2):276-290. Teimori F, Khaki AA, Rajabzadeh A, Roshangar L. The effects of 30 mT electromagnetic fields on hippocampus cells of rats. Surg Neurol Int. 2016 Jun 29;7:70.Kim S, Han D, Ryu J, Kim K, Kim YH. Effects of mobile phone usage on sperm quality - No time-dependent relationship on usage: A systematic review and updated meta-analysis. Environ Res. 2021 Nov;202:111784. iNTERPHONE Study Group. Brain tumour risk in relation to mobile telephone use: results of the INTERPHONE international case-control study. Int J Epidemiol. 2010 Jun;39(3):675-94. Carlberg M, Hardell L. Pooled analysis of Swedish case-control studies during 1997-2003 and 2007-2009 on meningioma risk associated with the use of mobile and cordless phones. Oncol Rep. 2015 Jun;33(6):3093-8. https://www.fda.gov/media/135043/downloadhttps://www.fcc.gov/consumers/guides/wireless-devices-and-health-concernsFrank JW. Electromagnetic fields, 5G and health: what about the precautionary principle? J Epidemiol Community Health. 2021 Jan 19:jech-2019-213595. Leszczynski D. The lack of international and national health policies to protect persons with self-declared electromagnetic hypersensitivity. Rev Environ Health. 2022 Oct 26;39(2):163-189. Cordelli E, Ardoino L, Benassi B, Consales C, Eleuteri P, Marino C, Sciortino M, Villani P, H Brinkworth M, Chen G, P McNamee J, Wood AW, Belackova L, Verbeek J, Pacchierotti F. Effects of radiofrequency electromagnetic field (RF-EMF) exposure on male fertility: A systematic review of experimental studies on non-human mammals and human sperm in vitro. Environ Int. 2024 Mar;

At Enterprise Connect 2025, David Sundstrom, Regional Sales Manager at LogiSense, highlighted how usage-based billing is transforming the way companies monetize software, AI, and connectivity services. Moving Beyond Seat-Based Pricing Traditionally, software and communications platforms relied on seat-based licensing, where businesses would buy a fixed number of user licenses. But as finance teams scrutinize renewals, questioning unused licenses and looking for cost efficiencies, enterprises are shifting to pay-as-you-go models. “A much more elegant way to monetize your product is what we call a usage-based or consumption-based model, where companies pay for what they use,” Sundstrom explained. LogiSense provides the billing infrastructure that enables businesses to move from static pricing to dynamic, real-time billing models. The shift comes with complexity—from tracking usage data to implementing flexible pricing structures—but LogiSense simplifies the process, making it easier for enterprises to roll out consumption-based services. Flexible Pricing Models Drive Growth A key advantage of LogiSense's platform is its ability to support diverse pricing models, including: Pay-per-use – Customers pay a fixed rate per event or interaction. Tiered pricing – Volume discounts reduce per-unit costs as usage increases. Pooled usage – Shared usage across an organization without individual licenses. Wallet-based billing – Prepaid drawdown models, commonly used in IoT and AI, where businesses commit to a spend level and use credits as needed. The AI Monetization Opportunity AI is reshaping industries, and LogiSense is positioned at the intersection of AI and monetization. According to Sundstrom, there are three primary ways companies are integrating AI into their revenue models: Enhancing existing services – AI is being used to automate processes and improve efficiency within existing platforms. Monetizing AI-driven tasks – Businesses are charging per AI-generated action, such as automated customer responses or data processing. Outcome-based billing – AI is delivering measurable results, and companies are shifting from activity-based billing to billing for successful outcomes. A leading example of outcome-based billing is Salesforce, which is monetizing AI-assisted tasks based on results rather than usage. LogiSense's billing platform supports this shift, allowing companies to charge based on the tangible value AI delivers. Why MSPs, MSSPs, and Carriers Should Pay Attention Managed service providers (MSPs), managed security service providers (MSSPs), and carrier service providers are also prime candidates for usage-based billing models. MSPs and MSSPs can bill clients based on service consumption, reducing waste and improving cost alignment. Carrier service providers can bill on behalf of their partners, allowing them to adopt flexible models without building custom billing solutions in-house. Where to Learn More For those interested in learning more about usage-based billing and LogiSense's solutions, the company's website, logisense.com, offers additional resources. Additionally, LogiSense will host the second annual Usage Economy Summit on November 5, 2025, in San Francisco. Following a successful inaugural event, this conference will bring together industry leaders to discuss the future of monetization, AI-driven billing models, and the impact of flexible pricing strategies. As enterprises rethink how they charge for their services, LogiSense is helping businesses adapt, scale, and grow with smarter, usage-based billing solutions. #EnterpriseConnect #LogiSense #UsageBasedBilling #SubscriptionEconomy #AI #Monetization #MSP #IoT

Deepak and Shray discuss the unexpected quirks and consequences of investing in mutual funds and pooled vehicles in general. The discussion covers how your returns and experiences can be impacted by other investors' actions, including issues with inflows, outflows, cutoff timings, and NAV calculations. Specific cases like DHFL, Yes Bank, and Zee promoter bonds are examined to highlight how complexities in pooled vehicles can affect investment decisions. Additionally, the episode provides insights on how to navigate these challenges and the importance of understanding the nature of pooled investments. 00:00 Introduction  00:43 Understanding Mutual Funds and Pool Vehicles 02:43 Complexities of Pool Vehicles 07:43 Impact of Inflows on Fund Composition 13:18 Challenges with Outflows and Debt Funds 20:00 Timing Issues and NAV Calculations 29:04 ETFs vs Mutual Funds: Arbitrage and Market Behavior 33:01 Case Studies: Yes Bank, DHFL, and Zee Promoter Bonds 37:50 Side Pocketing and Arbitrage 49:12 Investor Strategies and Market Timing Challenges 55:43 Conclusion and Final Thoughts

Dr. William Horan (Bristol Myers Squibb) joins AJP Audio to discuss a newly approved, novel treatment for schizophrenia spectrum disorder, which has potential impacts for cognition in patients.  Afterwards, AJP Editor-in-Chief Dr. Ned Kalin puts the rest of the March issue into context. 00:45     Horan interview 03:15     Novel mechanism of action in the treatment of schizophrenia 05:39     Side effect profiles 07:20     Clinical impacts 08:31     The need for further investigation 09:58     Limitations 11:05     Further research 13:08     Kalin interview 13:21     Horan et al. 17:34     Levenstein et al. 19:00     Fountoulakis et al. 20:57     Couture et al. 23:18     Stern et al. 27:35     McGirr et al. Transcript Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it. Subscribe to the podcast here. Listen to other podcasts produced by the American Psychiatric Association. Browse articles online. How authors may submit their work. Follow the journals of APA Publishing on Twitter. E-mail us at ajp@psych.org

Send us a textPooled compensation models are legal. In this episode, Captain Integrity Bob Wade discusses the compliance & legal risks when it comes to pooled compensation models. Hear how to make sure the units going into the pool are Fair Market Value (FMV), how to carefully select pool participants, how the compensation should be divided, Bob's swimming pool analogy, and some trivia about Two-Face from Batman. Learn more at CaptainIntegrity.com

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on United States Pooled Cohort Cardiovascular Disease Risk Scores in Adults With Diabetes Mellitus.

In June 2024, TTI's Roadside Safety and Physical Security Team crashed a Tesla Model 3 electric vehicle (EV) into a heavy-duty guardrail at 62 miles per hour. When the EV blew right through the barrier, researchers were stunned. TTI Senior Research Engineer Roger Bligh, whose 38 years of roadside safety barrier testing experience oversaw the test, joins guest host and TTI Agency Director Greg Winfree to discuss the results of the testing and the broader implications for standards governing the development and deployment of roadside safety devices. | View the Crash Test

JACC Associate Editor Theresa McDonagh, MBBCH  speaks with author Akshay S. Desai, MD, FACC about this paper on pulse pressure published in JACC and presented at AHA. In a pooled analysis of 16,950 patients with chronic HFmrEF or HFpEF enrolled from 4 global randomized clinical trials, a J-shaped relationship was observed between SBP and the risk of adverse CV events, with the lowest risk occurring at SBP values between 120 and 130 mmHg. A similar pattern was seen with PP, with the lowest risk found between 50 and 60 mmHg. Both higher SBP and higher PP independently predicted adverse CV events. Notably, PP remained a strong predictor of CV risk, independent of baseline SBP.

This week, Chris & Josh discuss the following topics (and so much more):   Pooled tips on the strip? Your Vegas anti bucket lists Listener questions So much more... Get registered today for Zorkfest 2024. Click here to get started. Want to contact us? Email: podcast@crapvegas.com Facebook: crapvegas.com/facebook Voicemail: crapvegas.com/voicemail Twitter: @VegasDuffy @SmallWhale13 @CrapVegas For more information, please visit our webpage at www.crapvegas.com or support us by becoming a Patreon subscriber at www.patreon.com/crapvegas  

This week on Ask Todd, Todd Lutsky explains how a pooled trust works and what scenarios they make the most sense in. Todd answers questions from the audience about protecting assets from the nursing home.

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Send a Text to the MomsWhat Will Happen When We're Gone? Trusts, Pooled Trusts and More-Ep. 99Guest: Megan Brand,  Colorado Fund for People with Disabilities Executive DirectorDani Page, JD (her other episodes with us are Episodes 50 and 70)In its simplest form, a Trust is a relationship, in which one person holds title to property, subject to an obligation to keep or use the property for the benefit of another..We ask:Can we use Trusts to help our loved ones with SMI - now, and after we are gone?Some of the differences between Pooled Trusts and Individual Trusts?How to evaluate Pooled Trust Organizations or other Trustees when considering who to name as trusteeHow does the Secure Act impact the ability to provide support through inherited IRA'sLanguage in trust documents to cloak our loved ones from creditors getting ahold of trust money needed to support their lives after we are dead.What can we set up now so that our loved ones will be okay after we are gone….and not to put a huge burden on their siblings?Links:https://www.cfpdtrust.org/www.cfpdtrust.org https://nationalplanalliance.org/programs/ https://aptrusts.org/Elder Law Attorneys:https://www.naela.org/Certified Elder Law Attorneys (CELA):https://www.americanbar.org/groups/senior_lawyers/resources/voice-of-experience/2010-2022/what-cela/Mindy and her book: https://mindygreiling.com/Randye and her book: https://www.randyekaye.com/Miriam and her book: https://www.miriam-feldman.com/iMOM PodcastIf you need a mom friend right now, you've come to the right place. On iMOM.com we...Listen on: Apple Podcasts SpotifyWant to know more?Join our facebook page Our websites:Randye KayeMindy Greiling Miriam (Mimi) Feldman

Commentary by Dr. Candice Silversides

In today's episode, we look at Terraform Labs' agreement to pay the United States SEC roughly $4.47 billion as part of its settlement with the securities regulator. Consensys-owned Ethereum wallet MetaMask has rolled out native pooled staking, Bitcoin mining stocks soared double digits after Donald Trump met with several U.S.-based mining firms, and TON has flipped Ethereum in daily active users — but is that the full story?Further reading:BREAKING: Terraform to pay $4.47B to resolve SEC civil lawsuitBitcoin miners rise 10% after Trump promises to back US minersTON flips ETH in daily active users, but that's not the full pictureCircle announces Solana programmable wallets, gas stationMetaMask enables pooled staking for Ethereum holdersGrab yourself a coffee, and let's get into today's episode!This episode of Rise'n'Crypto is brought to you by Cointelegraph and is hosted by Gareth Jenkinson. You can follow Gareth on Twitter.Rise'n'Crypto is brought to you by Cointelegraph and is hosted and produced by Robert Baggs. You can follow Robert on Twitter and LinkedIn. Cointelegraph's Twitter: @CointelegraphCointelegraph's website: cointelegraph.comThe views, thoughts and opinions expressed in this podcast are its participants' alone and do not necessarily reflect or represent the views and opinions of Cointelegraph. This podcast (and any related content) is for entertainment purposes only and does not constitute financial advice, nor should it be taken as such. Everyone must do their own research and make their own decisions. The podcast's participants may or may not own any of the assets mentioned.

Today's blockchain and cryptocurrency news Bitcoin is down slightly at $67,761 Eth is down slightly at $3,531 Binance Coin, down slightly at $610 MetaMask introduces pooled staking for ETH CMT digital aims for another $150M fund. PleasrDAO is taking Martin Shkreli to court Learn more about your ad choices. Visit megaphone.fm/adchoices

Commentary by Dr. Valentin Fuster

In the second part of this two-part podcast series, David Kirchner, Elliot Saavedra, and Jack Eckart from Ropes & Gray's benefits consulting group share their insights and experiences in collaborating with pooled employer plan ("PEP") providers. They discuss the process of bidding and vetting these providers on behalf of clients, while also delving into the crucial responsibilities that employers should consider when evaluating, monitoring, and selecting PEPs.

Renzo Protocol's ezETH LRT faces a depeg. Chainlink CCIP opens for general availability. Pooled stakers can now claim their STRK airdrop. And TreasureDAO launches Treasure Chain on testnet. Read more: https://ethdaily.io/450 Sponsor: Harpie is an onchain security solution that protects your wallet from theft in real time. Harpie helps you detect and block suspicious transactions before they execute, safeguarding your assets from malicious attacks and scams. Try Harpie for free at harpie.io/ethdaily. 

Is a pooled trust a Medicaid strategy for you? There are many tools one can use to plan for a Medicaid application. such as a pooled trust. -- I love comments. I make these videos specifically to help people with no expectations. Please take a second and say ‘Hi' in the comments and let me and know what you thought of the video… and p.s. It would mean the world to me if you hit the subscribe button.

Nikolaj Rosenthal is the Co-Founder and CEO of Myrmidon, a non-custodial staking provider. Nikolaj was a professional hockey player for +10 years and the first athlete to accept Bitcoin as a salary in 2017. He's been involved with crypto since late 2016, is an investor + entrepreneur, and was the CEO of cryptocurrency exchange Evonax.com. He went to Copenhagen Business School, where he holds a BSc. Business Administration and Service Management, and Msc. Organizational Innovation & Entrepreneurship.In this conversation, we discuss:- Being the first athlete to accept Bitcoin as salary in 2017- Non-custodial staking- Beaconchain, London fork, Merge, Shanghai/Capella & DenCun hardfork- DVT (Distributed validator technology)- ETH ETF- What's going on with Ethereum?- Solo-home staking- Staking as a service- Pooled staking- Centralized staking- How to pick the right staking provider?Myrmidon StakingWebsite: myrmidonstaking.comX: @MyrmidonstakingDiscord: discord.gg/kwE9EGnz96Nikolaj RosenthalInstagram: @nikolajrosenthalFacebook: @nikolaj.rosenthalLinkedIn: Nikolaj Rosenthal  ---------------------------------------------------------------------------------  This episode is brought to you by PrimeXBT.  PrimeXBT offers a robust trading system for both beginners and professional traders that demand highly reliable market data and performance. Traders of all experience levels can easily design and customize layouts and widgets to best fit their trading style. PrimeXBT is always offering innovative products and professional trading conditions to all customers.   PrimeXBT is running an exclusive promotion for listeners of the podcast. After making your first deposit, 50% of that first deposit will be credited to your account as a bonus that can be used as additional collateral to open positions.  Code: CRYPTONEWS50  This promotion is available for a month after activation. Click the link below:  PrimeXBT x CRYPTONEWS50

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Farmed Animal Funders' Request for Proposals: Pooled Fund Ideas Towards Ending Factory Farming, published by Zoë Sigle on April 5, 2024 on The Effective Altruism Forum. Farmed Animal Funders is soliciting proposals for pooled fund ideas that will fill an unmet, yet high-impact, charitable intervention playing a critical role in the movement to end factory farming. Proposals are due by May 31st, 2024. Farmed Animal Funders (FAF) is a donor community made up of individuals and foundations giving more than $250,000 per year to end factory farming. A pooled fund from FAF members and new donors can play an important role to fill financial gaps across multiple nonprofits while relying on unique expertise to impactfully distribute funds. We are seeking pooled fund proposals that meet the following criteria: The proposal supports efforts to end factory farming. The specific theory of change, strategy, intervention, or geography is unlikely to receive sufficient funding to meet the need/problem without the attention of a pooled fund. The projected animal impact of this pooled fund is exceptionally high. Multiple organizations can effectively absorb and deploy at least $1 to $3 million USD, or more for exceptional opportunities, combined over a defined period of funding (e.g., 1 year, 3 years) to advance the proposed work. We encourage collaboration where strategic and enthusiastically supported by all organizations. One or more people have unique subject matter expertise to meaningfully evaluate and advise on grant applications. Suggestions of specific advisors (which might be you) are preferred, but not required. Pooled fund themes could range from specific geographies, specific interventions, or specific time-sensitive opportunities. As one example, FAF previously hosted a pooled fund for organizations working on farm animal welfare policy in Europe based on a time-sensitive legislative opportunity that benefited from legislative advocacy efforts across several countries. We encourage creativity! We are also open to supporting existing pooled funds that have an unmet financial need. We will evaluate pooled fund ideas based on: How well they meet the criteria listed above. How interested FAF members are in funding as a pool (rather than funding organizations directly and individually). This depends on factors like member interest in the topic and whether funders' in-house advisory expertise is sufficient or not for evaluation. Potential to recruit new funders to the movement to end factory farming, such as with novel issue framing. We intend to review proposals, including potential follow-up questions or calls, in June 2024. Top proposals will be shared with FAF members for feedback. If any ideas are selected, FAF intends to: Raise funds for the pool from existing FAF members and relevant prospective funders seeking high-impact opportunities to give. Distribute grant applications to relevant nonprofit organizations. Identify and select subject matter experts to advise on grant evaluations. Evaluate grant applications with selected fund advisors and FAF members to make funding decisions. Distribute funds to selected nonprofits organizations. To formally submit a proposal for a pooled fund: Please submit a document no longer than two pages to pooled-fund@farmedanimalfunders.org by May 31st, 2024 with the following: Email subject: Pooled Fund RFP Your name, affiliation(s), and contact information (email, phone, and address). Description of the pooled fund idea, including the suggested organizations involved, timeframe, potential expert advisors, and funding need/request. Description of how the idea meets each of the described criteria. We are more interested in the content of the proposal, so no need to invest time into formatting. If you prefer early feedback on one or more id...

The White House is seeking a bigger budget to spur hiring efforts across government. Led by the Office of Personnel Management, the Biden administration is pushing for a focus on pooled hiring, early-career talent development, and even the HR workforce. The priorities aren't necessarily new. But OPM is hoping some added funding can scale things up. Joining the Federal Drive with more, Federal News Network's Drew Friedman. Learn more about your ad choices. Visit megaphone.fm/adchoices

The White House is seeking a bigger budget to spur hiring efforts across government. Led by the Office of Personnel Management, the Biden administration is pushing for a focus on pooled hiring, early-career talent development, and even the HR workforce. The priorities aren't necessarily new. But OPM is hoping some added funding can scale things up. Joining the Federal Drive with more, Federal News Network's Drew Friedman. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In part one of this two-part podcast series, David Kirchner and Elliot Saavedra of the Ropes & Gray benefits consulting group, revisit one of the biggest advances in retirement plan design in recent memory: pooled employer plans (“PEPs”). Based on their findings from a survey they conducted of several of the leading providers in this space and their experiences with this new, innovative approach to employer-sponsored retirement plans, they take a fresh look at PEPs and how the market has evolved over the last three years. Stay tuned for part two, where they will dive deeper into the responsibilities that employers should be mindful of when considering, evaluating and monitoring PEPs, as well as recent regulatory changes impacting PEPs

Over the next year, the Office of Personnel Management is planning to expand on one recruitment strategy that has already seen small-scale success: pooled hiring.“You're going to see a continuing emphasis on that because it just makes sense from a resource perspective,” OPM Deputy Director Rob Shriver said in an interview with Federal News Network.Pooled hiring takes place when one agency, who's already hired the candidates it needs off a list of qualified applicants, then shares that list with other agencies looking to onboard candidates for the same position. It can be particularly beneficial, for instance, to agencies who may have fewer HR resources, if they can lean on larger agencies and departments for support. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Over the next year, the Office of Personnel Management is planning to expand on one recruitment strategy that has already seen small-scale success: pooled hiring. “You're going to see a continuing emphasis on that because it just makes sense from a resource perspective,” OPM Deputy Director Rob Shriver said in an interview with Federal News Network. Pooled hiring takes place when one agency, who's already hired the candidates it needs off a list of qualified applicants, then shares that list with other agencies looking to onboard candidates for the same position. It can be particularly beneficial, for instance, to agencies who may have fewer HR resources, if they can lean on larger agencies and departments for support. Learn more about your ad choices. Visit megaphone.fm/adchoices

Individual Patient-data Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure at 6 Months in the RADIANCE Clinical Trial Program

In the Season 2 JPIA Five finale, ACWA JPIA's Communication and Outreach Specialist, Molly Quirk, introduces Jennifer Jobe, ACWA JPIA Director of Pooled Programs. With nearly two decades of risk management experience, Jennifer emphasizes her role in overseeing coverage programs and alternative risk financing at the JPIA. Jennifer also covers her background, FAQs, and current water industry trends, highlighting the importance of ACWA JPIA member education and service utilization, and addressing recent member challenges such as catastrophic property losses and cyber threats.

Lee Crockett joins us to share his expertise as the executive director of the Shark Conservation Fund (SCF). Lee shares how donors founded SCF and pooled funds to form strategic partnerships that conserve the shark population. Lee explains the difference between the regular nonprofit and the pooled donor strategy, while also offering words of wisdom for those using this strategy. Episode Highlights:The History of The Shark Conservation Fund (SCF)International CollaborationThe difference between a regular nonprofit and a pooled fund like SCFLee Crockett Bio:As executive director of the Shark Conservation Fund (SCF), Lee is responsible for designing and implementing programmatic and grantmaking strategies, managing SCF's grantmaking portfolio and staff, forming strategic partnerships with NGOs and other funders, fundraising, ensuring strong operations and governance, and representing the SCF to governments, NGOs, philanthropists, and the public.Prior to joining the SCF, Lee spent 20 years working on fisheries management at the state, interstate, federal, and international levels with both the US. Government and the non-profit sector. Most recently, he was the Director of U.S. Oceans for The Pew Charitable Trusts where he led Pew's efforts to establish policies to end overfishing and promote ecosystem-based fisheries management. Before joining Pew, Crockett was executive director of the Marine Fish Conservation Network, the largest U.S. coalition dedicated to promoting the sustainable management of ocean fish. Prior to that, he was a fishery biologist with the National Oceanic and Atmospheric Administration's Fisheries Service, leading agency efforts to protect essential fish habitat. He also served as a staff member of the U.S. House of Representatives Committee on Merchant Marine and Fisheries.Crockett holds a bachelor's degree in biology and a master's degree in biological oceanography from the University of Connecticut.Links:Marine Fish Conservation Network https://conservefish.orgShark Conservation Fund https://www.sharkconservationfund.org CITIES https://cites.org/eng/disc/species.php If you enjoyed this episode, listen to these as well: https://www.doyourgood.com/blog/88-elizabeth-basthttps://www.doyourgood.com/blog/95-Guide-Rahrhttps://www.doyourgood.com/blog/148-Sybil-Speak-The-Ins-and-Outs-of-Donor-Advised-Funds-and-Pooled%20Funds Crack the Code: Sybil's Successful Guide to Philanthropy Become even better at what you do as Sybil teaches you the strategies as well as the tools you'll need to avoid mistakes and make a career out of philanthropy.Sybil offers resources that include special free short video mini-courses, templates, and key checklists, and words of advice summarized in easy-to-view PDFs. Check out Sybil's website with all the latest opportunities to learn from Sybil athttps://www.doyourgood.com Connect with Do Your Good https://www.facebook.com/doyourgood https://www.instagram.com/doyourgood Would you like to talk with Sybil directly? Send in your inquiries through her website https://www.doyourgood.com/ or you can email her directly at sybil@doyourgood.com!

Commentary by Dr. Valentin Fuster

Sybil delves into Donor Advised Funds (DAFs) and Pooled Funds. DAFs have been gaining prominence recently, with a significant share of annual giving directed towards them. Sybil explains the three categories of DAFs and pooled funds, with examples and pros/cons for each type. She then shares the criticisms and the benefits of DAFs.Episode Highlights:The three categories of DAFs and pooled fundsThe criticisms of DAFsThe essential benefits DAF.Sybil Ackerman-Munson Bio:With over 20 years of experience as a nonprofit professional and foundation advisor, I work with philanthropic institutions and foundations interested in successful, high-impact grant-making so you can make a real and lasting positive contribution to the world on your terms.Links:Bank of America https://www.privatebank.bankofamerica.com/solutions/donor-advised-fund.htmlBridgespan https://www.bridgespan.org/our-services/helping-foundations-collaborate-with-other-fundersCharities Aid Foundation https://www.cafonline.org/my-personal-giving/long-term-givingFidelity Charitable https://www.fidelitycharitable.org Morgan Stanley https://www.morganstanley.com/campaigns/wealth-management/giftNational Christian Foundation https://www.ncfgiving.com/solutions/giving-fund National Philanthropic Trust https://www.nptrust.org/donor-advised-funds/open-daf-accountPew Charitable Trusts https://www.pewtrusts.org/enOregon Community Foundation* https://oregoncf.org/ways-to-give/choose-your-fund/donor-advised-fundResources Legacy Fund https://resourceslegacyfund.orgPanorama Global https://www.panoramaglobal.org/fundsShark Conservation Fund https://www.sharkconservationfund.org Vanguard https://www.vanguardcharitable.orgArticle by Drew Lindsay https://www.philanthropy.com/article/a-short-history-of-the-fast-and-furious-rise-of-dafsArticle by Helen Flanery https://inequality.org/great-divide/top-public-charitiesIf you enjoyed this episode, listen to these as well: https://www.doyourgood.com/blog/146-measuring-effectiveness-of-relationships-between-grantees-donorshttps://www.doyourgood.com/blog/46-tim-millerhttps://www.doyourgood.com/blog/144-how-to-measure-success-in-philanthropy Crack the Code: Sybil's Successful Guide to Philanthropy Become even better at what you do as Sybil teaches you the strategies as well as the tools you'll need to avoid mistakes and make a career out of philanthropy.Sybil offers resources that include special free short video mini-courses, templates, and key checklists, and words of advice summarized in easy-to-view PDFs. Check out Sybil's website with all the latest opportunities to learn from Sybil athttps://www.doyourgood.com Connect with Do Your Good https://www.facebook.com/doyourgood https://www.instagram.com/doyourgood Would you like to talk with Sybil directly? Send in your inquiries through her website https://www.doyourgood.com/ or you can email her directly at sybil@doyourgood.com!

Group investing can give you advantages that might be beyond the reach of individual investors. So today, Travis Smith will shed light on this type of investment strategy and how his company, Tribevest, provides a streamlined process for maximizing returns in your real estate deals. Tune into this episode to find out more! KEY TAKEAWAYSA beginner's guide to group investing in TribevestThe importance of transparency in investment platforms What is an open tribe and the perks of investing in it Differences between open, pro, and basic real estate tribes Reasons to invest in groups instead of other pooled funds RESOURCES/LINKS MENTIONEDEp365a 3 Key Things to Understand About Apartment Syndication: https://shorturl.at/hkJRS Ep365b 3 Key Things to Understand About Being a Limited Partner: https://shorturl.at/mHLMY Ep365c 3 Key Questions to Ask About a Deal: https://shorturl.at/wELT7 ABOUT TRAVIS SMITHTravis is the founder and CEO of an all-in-one platform, a safe place to assemble tribes, align, file LLC, author the bylaws, open a business bank account, and efficiently pool capital from a member. The platform is called Tribevest, the easiest way to launch an investor entity, pool capital, and experience wealth-building with friends, family, and people you trust. CONNECT WITH TRAVISWebsite: Tribevest: https://www.tribevest.com/ CONNECT WITH USSchedule a 20-min get-to-know each other call - bit.ly/3OK31kISchedule a 20-min call to explore performance coaching - bit.ly/Coaching-JulieSchedule a 30-min call to learn about investing with Three Keys Investments - bit.ly/3yteWhxJoin the Book and Networking club via Zoom at: bit.ly/3HBPnQw or sign up at: bit.ly/3c0dr1uVisit ThreeKeysInvestments.com to download a free e-book, “Why Invest in Apartments”!Learn how to reduce your tax liability by scheduling a FREE consultation at https://modewealth.com/If you're looking for an affordable healthcare solution, check out Christian Healthcare Ministries by visiting https://bit.ly/3JTRm1IPlease RSS: Review, Subscribe, Share!

On this episode of Data Driven, BAILeY and Frank La Vigne welcome special guest Lauren Tickner to discuss strategies for maximizing time and success in the digital age. Lauren shares her insights on motivation, dealing with online haters, and the power of automation in business. The conversation delves into the importance of understanding risks and rewards, breaking free from traditional career paths, and the benefits of working in startups or entrepreneurial businesses. Lauren also provides valuable tips on social media content creation, utilizing storytelling and personalization to engage readers. Additionally, she introduces the PASTA framework for creating compelling social media posts and shares her approach to tracking and optimizing the client journey. Moments[00:01:16] The podcast uses a British voiceover actor to differentiate from East Coast accents. An AI voice named Bailey was later used, which can now be animated.[00:06:19] Successful asset manager quits job to pursue fitness career using social media. Simplifies life and focuses on selling premium packages. Finds success with minimal monthly sales.[00:08:05] The speaker discusses their upbringing in New York and the pressure to work in the financial industry. They admire the listener's decision to break free from that path and simplify things. They also comment on the listener's sense of humor and social media presence.[00:13:00] To simplify social media content creation: automate posting to multiple platforms, identify 5 topics to focus on, add personal storytelling to engage readers, and include a call to action to prompt specific actions.[00:19:41] The text discusses creating and sharing content for three different audience groups based on their familiarity with the author. It suggests using different types of content for each group, such as introducing oneself to new audiences, showcasing expertise to familiar audiences, and offering opportunities to become clients. The author also talks about segmenting content into top, middle, and bottom of the funnel, and using different calls to action to gauge audience interest.[00:24:09] Data shows that clients who watch 2 case studies before joining stay longer. We track client journey and added quick welcome call within 4 hours of joining for positive experience. Pooled calendar allows immediate availability for calls.[00:27:46] The author explains their approach to managing their business, aiming for a smaller internal company and owning multiple businesses rather than having a large team and many clients.[00:31:58] We should focus on the potential benefits, not just the downsides. Make realistic lists of what could go right and wrong. Replace "time" with "life" to make better decisions. Consider leaving high-paid jobs for startups or entrepreneurial businesses. Showcase the value you can bring to companies.[00:34:17] The speaker finds the content interesting and praises the concept, emphasizing the key takeaway. They inquire about finding more information.

The show scratches off their lottery tickets they bought with pooled money. Find out where they got the tickets and if anyone won any money! Plus, hear why there is a crazy illness going around the studio right now, who is sick, and why everyone thinks Lunchbox started it. Then, Lunchbox thinks people don't know how to do a garage sale the right way anymore, find out what happened after he recently went to one and his suggestions!See omnystudio.com/listener for privacy information.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Diego Raimondo and Giulia Rovero. Dr. Raimondo works as medical director and assistant researcher at the Division of Gynecology and Pathophysiology of Human Reproduction, Bologna, Italy, directed by Prof. Renato Seracchioli. He received his PhD on new technologies for endometriosis surgical removal from the University of Bologna in 2021. He is an Advisory Board Member of the ESGE (European Society for Gynaecological Endoscopy) and member of the Special Interest Group in Robotics. His research interests are focused on minimally invasive surgery (laparoscopic, robotic and hysteroscopic) for endometriosis and endometrial cancer. Dr. Giulia Rovero graduated in Medicine in 2017 at the University of Florence. She is currently a fifth-year resident at the Division of Gynecology and Pathophysiology of Human Reproduction, Bologna, Italy, directed by Prof. Renato Seracchioli. In 2022/23 she spent twelve months at the Lariboisiere Hospital in Paris focusing on gynecologic oncology. She is developing her research activity in collaboration with Dr. Raimondo in the field of minimally invasive surgery for endometrial cancer.    Highlights: In endometrial carcinoma (EC) patients, the rate of sentinel lymph node (SLN) mapping failure ranges from 20% to 25%. Pooled data assessing predictive factors of SLN mapping failure in EC patients undergoing SLN biopsy through the cervical injection of indocyanine green (ICG) are lacking. ICG dose 30 kg/m2, menopausal status, adenomyosis) nor surgical history is significantly associated with SLN mapping failure in EC patients. Deep myometrial invasion, FIGO grade 3, non-endometrioid histotype, and lymphovascular space invasion are not significantly associated with SLN mapping failure in EC patients.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Diego Raimondo and Giulia Rovero. Dr. Raimondo works as medical director and assistant researcher at the Division of Gynecology and Pathophysiology of Human Reproduction, Bologna, Italy, directed by Prof. Renato Seracchioli. He received his PhD on new technologies for endometriosis surgical removal from the University of Bologna in 2021. He is an Advisory Board Member of the ESGE (European Society for Gynaecological Endoscopy) and member of the Special Interest Group in Robotics. His research interests are focused on minimally invasive surgery (laparoscopic, robotic and hysteroscopic) for endometriosis and endometrial cancer. Dr. Giulia Rovero graduated in Medicine in 2017 at the University of Florence. She is currently a fifth-year resident at the Division of Gynecology and Pathophysiology of Human Reproduction, Bologna, Italy, directed by Prof. Renato Seracchioli. In 2022/23 she spent twelve months at the Lariboisiere Hospital in Paris focusing on gynecologic oncology. She is developing her research activity in collaboration with Dr. Raimondo in the field of minimally invasive surgery for endometrial cancer. Highlights: * In endometrial carcinoma (EC) patients, the rate of sentinel lymph node (SLN) mapping failure ranges from 20% to 25%. * Pooled data assessing predictive factors of SLN mapping failure in EC patients undergoing SLN biopsy through the cervical injection of indocyanine green (ICG) are lacking. * ICG dose 30 kg/m2, menopausal status, adenomyosis) nor surgical history is significantly associated with SLN mapping failure in EC patients. * Deep myometrial invasion, FIGO grade 3, non-endometrioid histotype, and lymphovascular space invasion are not significantly associated with SLN mapping failure in EC patients.

Dial in to discover what is a pooled investment vehicle and how it can be a powerful strategy for you as a passive investor or deal sponsor in this episode with Lance Pederson. If you want to integrate it into your real estate deals, learn the fundamentals and drive your business to success by tuning in!WHAT YOU'LL LEARN FROM THIS EPISODE What is a pooled investment vehicle and how does it work?Usual clients that want to leverage a pooled investment vehicleSteps to structuring a pooled investment vehicle The importance of setting clear investment fund goalsWhy now's the best time to accept and understand investing risks ABOUT LANCE PEDERSON Lance currently serves as the CEO of Parsons Villas. As CEO, he ensures the team is in constant alignment and continually focuses on achieving strategic objectives that will propel the firm toward fulfilling its mission and vision. He also heads up the Capital Management arm of the company, where he leads capital raising and manages the day-to-day operations of the company's recently launched investment fund. Since 2012, Lance has helped over 200 real estate entrepreneurs form pooled investment funds. His passion continues working with them to help grow and scale their firms by leveraging the power of pooled investment vehicles while hosting his upcoming podcast – Death of 60/40 – targeted at high net-worth passive investors interested in allocating capital into real estate private placements and alternative investments in general. CONNECT WITH LANCE Website: Resonance Capital Group: http://lancepederson.com Podcast: Death of 60/40: https://deathof6040.com/Email: lance@lancepederson.com CONNECT WITH USWant a list of top-rated real estate conferences, virtual meetups, and mastermind groups? Send Tate an email at tate@glequitygroup.com to learn more about real estate using a relational approach.Looking for ways to make passive income? Greenlight Equity Group can help you invest in multifamily properties and create consistent cash flow without being a landlord. Book a consultation call and download Tate's free ebook, "F.I.R.E.-Financial Independence Retire Early via Apartment Investing," at www.investwithgreenlight.com to start your wealth-building journey today!

Matt Burk Ep #787 - Syndication vs. Pooled Investment Fund   Founder, CEO and Chairman of Fairway America and Verivest. Seasoned real estate executive, Chief Investment Officer, and fund manager who started and managed eleven (11) real estate asset based Reg D pooled investment funds over more than 22 years. Discretionary underwriter/approval authority of thousands of real estate asset based investments with total asset value in the billions, including pooled investment funds, real estate secured loans (newly originated and discounted acquisitions), syndications, participations, GP and LP equity interests, and more.   Here's some of the topics we covered:   Different Types of Syndications The Deals You Take Down Determine Your Deal Structure How To Influence an Investor Into Your Fund Passive Investing In Pooled Funds To find out more about partnering or investing in a multifamily deal: Text Partner to 72345 or email Partner@RodKhleif.com    Please Review and Subscribe  

Videos: 6 minutes ago : Elon Musk Shared Terrifying Message (8:39) You're Not Going To Believe This! | Mark Steyn & Eva Vlaardingerbroek (3:03) Tulsi Gabbard News Live/ Tulsi Shares The True Reason Of Her Exit (3:13) Neil Oliver – ‘…it's a toxic hell…' (START @ 9:00) So THIS is how they plan to screw these companies, from inside out | Redacted with Clayton Morris (2:48)   Pomegranate juice found to combat systemic inflammation throughout the body University of Bologna (Italy) & University of Auckland (New Zealand), November 18, 2022 The researchers from the University of Bologna and the University of Auckland looked at the effects of the juice of the pomegranate in particular, which has already been shown to help conditions like diabetes, atherosclerosis and prostate cancer. Chronic inflammation, a response by the body to infection and tissue damage, has been linked to the development of disorders such as inflammatory bowel disease, asthma, rheumatoid arthritis, chronic obstructive pulmonary disease and psoriasis. After analyzing an extensive number of existing studies on pomegranate, they found plenty of evidence that shows pomegranate juice can indeed help inflammation-related diseases, although they pointed out that a definitive relationship has not been officially established. Most of the scientific research on pomegranate's health benefits has been carried out on cell culture or animal models, they point out, and clinical trials with humans are generally lacking. They found that pomegranate seems to show the most promise in fighting cardiovascular diseases, metabolic syndrome and diabetes, but the researchers urge care, calling on further studies to determine its specific effects and explain why the fruit juice seems to help chronic inflammatory diseases. A Case Western study published in the Journal of Inflammation, for example, found that the extract of pomegranate significantly inhibited the buildup of damaging proteins associated with Alzheimer's disease by as much as a half. This effect is being attributed to its ability to protect against the oxidative stress that leads to beta-amyloid deposits. Researchers have also demonstrated its potential to help those with prostate, colon and breast cancer. In studies where tumor cells were treated with pomegranate, cell migration dropped and the cancer was stopped from spreading to other areas of the body. Pomegranate juice came out on top in a study of beverages known for their antioxidant content carried out by the Center for Human Nutrition at the University of California – Los Angeles's David Geffen School of Medicine. While all of the beverages examined – blueberry juice, acai berry juice, green tea, white tea, Concord grape juice, orange juice, pomegranate juice and red wine, had impressive amounts of antioxidants, pomegranate juice outperformed them all when it came to polyphenols and protective benefits. Its antioxidant potency composite index was a full 20 percent higher than any of the other drinks that were put through the rigorous testing. (NEXT) Handful of walnuts daily cuts risk of asthma University of North's Carolina, November 20, 2022 Here's another reason for you to eat more walnuts as a type of vitamin E, found in these nuts, may prevent the risk of asthma attacks by reducing airway inflammation. According to researchers, sufferers of a common breathing condition, taking it as part of the study, were also found to have less sticky mucus in their lungs. Gamma-tocopherol is a major form of vitamin E, which is abundant in nuts like walnuts and pecans and in the legume peanut, as well as seed oils such as corn, soybean and sesame. Senior study author Professor Michelle Hernandez from the University of North's Carolina school of medicine said epidemiologic data suggested that people with high amounts of vitamin E in their diet were less prone to asthma and allergic disease. The team randomly analysed participants into two groups, one that received gamma tocopherol supplement and other that received a placebo for two weeks. After a three-week period break, the findings indicated that when people were taking the vitamin E supplement, they had less eosinophilic inflammation. In addition, those who were taking vitamin E were also found to have lower levels of proteins called mucins, which affect the stickiness of mucus. Mucins are often elevated in asthmatics. (NEXT) Using vapes may set the stage for dental decay Tufts University, November 23, 2022 A vaping habit could end up leading to a tarnished smile, and more frequent visits to the dentist. Research by faculty from Tufts University School of Dental Medicine found patients who said they used vaping devices were more likely to have a higher risk of developing cavities. With CDC surveys reporting that 9.1 million American adults—and 2 million teenagers—use tobacco-based vaping products, that means a lot of vulnerable teeth. The findings of this study on the association between vaping and risk of caries—the dental term for cavities—serve as an alert that this once seemingly harmless habit may be very detrimental, says Karina Irusa, assistant professor of comprehensive care and lead author on the paper. The study was published in The Journal of the American Dental Association. Irusa says that the recent Tufts finding may be just a hint of the damage vaping causes to the mouth. “The extent of the effects on dental health, specifically on dental decay, are still relatively unknown,” she says. “At this point, I'm just trying to raise awareness,” among both dentists and patients. This study, Irusa says, is the first known specifically to investigate the association of vaping and e-cigarettes with the increased risk for getting cavities. She and her colleagues analyzed data from more than 13,000 patients older than 16 who were treated at Tufts dental clinics from 2019-2022. While the vast majority of the patients said they did not use vapes, there was a statistically significant difference in dental caries risk levels between the e-cigarette/vaping group and the control group, Irusa found. Some 79% of the vaping patients were categorized as having high-caries risk, compared to just about 60% of the control group. The vaping patients were not asked whether they used devices that contained nicotine or THC, although nicotine is more common. It's also been observed that vaping seems to encourage decay in areas where it usually doesn't occur—such as the bottom edges of front teeth. “It takes an aesthetic toll,” Irusa says. (NEXT) Study finds link between foods scored higher by new nutrient profiling system and better long-term health outcomes Tufts University, November 22, 2022 The idea that what we eat directly affects our health is ancient; Hippocrates recognized this as far back as 400 B.C. But, identifying healthier foods in the supermarket aisle and on restaurant menus is increasingly challenging. Now, researchers at the Friedman School of Nutrition Science and Policy at Tufts have shown that a holistic food profiling system, Food Compass, identifies better overall health and lower risk for mortality. In a paper published in Nature Communications, researchers assessed whether adults who ate more foods with higher Food Compass scores had better long-term health outcomes and found that they did. Introduced in 2021, Food Compass provides a holistic measure of the overall nutritional value of a food, beverage, or mixed meal. It measures nine domains of each item, such as nutrient ratios, food-based ingredients, vitamins, minerals, extent of processing, and additives. Based on scores of 10,000 commonly consumed products in the U.S., researchers recommend foods with scores of 70 or above as foods to encourage; foods with scores of 31-69 to be eaten in moderation; and anything that scores 30 or below to be consumed sparingly. For this new study, Food Compass was used to score a person's entire diet, based on the Food Compass scores of all the foods and beverages they regularly consume. For this validation study, researchers used nationally representative dietary records and health data from 47,999 U.S. adults aged 20-85 who were enrolled between 1999-2018 in the National Health and Nutrition Examination Survey (NHANES). Deaths were determined through linkage with the National Death Index (NDI). Overall, researchers found that the mean Food Compass score for the diets of the nearly 50,000 subjects was only 35.5 out of 100, well below ideal. “One of the most alarming discoveries was just how poor the national average diet is,” said O'Hearn. “This is a call for actions to improve diet quality in the United States.” A higher Food Compass diet score was associated with lower blood pressure, blood sugar, blood cholesterol, body mass index, and hemoglobin A1c levels; and lower prevalence of metabolic syndrome and cancer. A higher Food Compass diet score was also associated with lower risk of mortality: for each 10-point increase, there was a 7 percent lower risk of death from all causes. Food Compass also boosts scores for ingredients shown to have protective effects on health, like fruits, non-starchy vegetables, beans and legumes, whole grains, nuts and seeds, seafood, yogurt, and plant oils; and lowers scores for less healthful ingredients like refined grains, red and processed meat, and ultra-processed foods and additives. “We know Food Compass is not perfect,” said Mozaffarian. “But, it provides a more comprehensive, holistic rating of a food's nutritional value than existing systems, and these new findings support its validity by showing it predicts better health.” (NEXT) Acupuncture can relieve lower back and pelvic pain often experienced during pregnancy Guangzhou University of Chinese Medicine, November 21, 2022 Acupuncture can significantly relieve the lower back and/or pelvic pain frequently experienced by women during their pregnancy, suggests a pooled data analysis of the available evidence, published in BMJ Open. And there were no observable major side effects for newborns whose moms opted for the therapy, the findings indicate, although only a few of the published studies included in the analysis evaluated outcomes, such as premature birth, note the researchers. To add to the evidence base, the researchers trawled research databases for relevant clinical trials that compared the pain relief afforded to pregnant womengiven acupuncture, alone or when combined with other therapies, with other/no/dummy treatments, as well as the potential impact on their newborns. The final analysis included 10 randomized controlled trials, involving 1,040 women. Every study was published between 2000 and 2020, and carried out variously in Sweden, the UK, the U.S., Spain and Brazil. The moms-to-be were all healthy, 17 to 30 weeks into their pregnancy on average, and had lower back and/or pelvic pain. Pooled data analysis of the trial results for nine studies suggested that acupuncture significantly relieved pain during pregnancy. Four of those studies reported on the potential of acupuncture to restore physical function, and the results showed that this was significantly improved. Quality of life was recorded in five studies. When the results of these were pooled, the findings suggested that acupuncture significantly improved this too. Pooled data analysis of four studies indicated that there was a significant difference in overall effects when acupuncture was compared with other or no interventions. The researchers conclude that acupuncture merits closer attention for its potential to ease pain at a time when it's preferable to avoid drugs because of their potential side effects for mother and baby. (NEXT) 6 Health Benefits Of Rutin, And Where To Find It GreenMedInfo, November 24, 2022 Rutin is an antioxidant and anti-inflammatory powerhouse found in a variety of delicious food that may boost your health via multiple avenues, from promoting healthy circulation to providing pain relief. Rutin is one of about 4,000 types of flavonoids that are found abundantly in plants. Also known as rutoside and vitamin P, rutin is a flavonol that acts as an active constituent in tea leaves, apples, buckwheat, most citrus fruits and passion flower, for example, with nutraceutical effects that have been valued since ancient times. Medicinal plant compounds often have a range of biological activities that are both impressive and varied. Rutin is no exception, with a number of pharmacological activities that include: Six Top Reasons to Try Rutin Rutin is perhaps best known for its ability to ward off oxidative stress via potent antioxidant properties. This makes it valuable in a number of disease conditions and even as a tool for healthy aging. Rutin, for instance, reduces skin aging by strengthening dermal density and elasticity, and is found in more than 130 registered therapeutic medicinal preparations. GreenMedInfo.com has additionally compiled nearly 70 pharmacological actions related to rutin, along with 136 diseases that it may be useful for. Some of its top health benefits follow. Protection From Neurodegenerative Disease Rutin has demonstrated benefits to the central nervous system, including prevention of neuroinflammation, anticonvulsant activity and antidepressant effects. Rutin may be useful for recovery after stroke and also shows promise for Alzheimer's disease. With an ability to cross the blood-brain barrier, rutin may benefit the cognitive and behavioral symptoms of neurodegenerative diseases and helps to remove the inflammatory component of neurodegeneration. Relieve Arthritis Pain Rutin not only has analgesic and antinociceptive effects but also antiarthritic effects, making it an ideal natural option for arthritis.The plant compound has been found to suppress oxidative stress in people with rheumatoid arthritis,while also inhibiting both the acute and chronic phases of inflammation in an arthritis rat model. Antidiabetic Effects Rutin has beneficial effects on the endocrine system, including antidiabetic and anti-hypercholesterolemic effects. Rutin helps fight diabetes by decreasing carbohydrates absorption from the small intestine, increasing the uptake of glucose into tissues and stimulating the secretion of insulin from beta cells, leading to antihyperglycemic effects as well as protection against the development of diabetic complications. Rutin is also useful for protecting against age-related metabolic dysfunction, with research suggesting it inhibits age-related mitochondrial dysfunction and oxidative stress, as well as endoplasmic reticulum, or ER, stress, which is related to proteins that are not properly folded. Promote Healthy Circulation and Reduce Blood Clots Consuming rutin, either from foods or supplements, may be an effective way to block the formation of blood clots. Research by Harvard Medical School researchers suggests that rutin is effective against both platelet-rich clots that form in arteries and fibrin-rich clots that form in veins. Rutin was found to be a “champion compound” for inhibiting protein disulfide isomerase (PDI), which plays a role in the initial stages of clot formation. A nano-formulation of rutin was also found to exert powerful antithrombotic effects by inhibiting PDI,while rutin may also augment the production of nitric oxide in human endothelial cells, which is useful for blood pressure and cardiovascular system health. In terms of improved circulation, rutin is a venoactive compound, which means it may be useful for symptoms of chronic venous diseases (CVD). The compound has been demonstrated to reduce severity of lower leg pain, leg cramps, heaviness and itching, as well as edema (swelling), in people with CVD. Anticancer Effects Rutin's anticancer properties have been extensively studied. In human leukemia cells, rutin led to a significant reduction in tumor size, and it's known to inhibit cancer cell growth by cell cycle arrest and apoptosis. It also inhibits proliferation and metastasis of colorectal cancer cell lines and shows promise for use in ovarian and color cancers, as well as neuroblastoma. Support Gastrointestinal Health Rutin has antiulcer effects, as it inhibits the gastric proton pump that sends acid to your stomach. It also has potential against inflammatory bowel disease, not only due to its antioxidant effects but also by suppressing the release of proinflammatory mediators and the expression of inflammatory proteins. Top Sources of Rutin As noted in the Saudi Pharmaceutical Journal, “An ancient saying ‘an apple a day, keeps doctor away' seems to be true as rutin, one of the important constituents of apples, has a wide array of biological activities.”